Needham analyst Gil Blum has maintained their bullish stance on ACLX stock, giving a Buy rating today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gil Blum has given his Buy rating due to a combination of factors surrounding Arcellx Inc’s promising developments. The company’s anito-cel therapy has shown encouraging results in the pivotal iMMagine-1 study for multiple myeloma, with progression-free survival rates comparable to existing treatments like Carvykti, but without the associated toxicities. This positions anito-cel as a potentially superior option in the CAR-T therapy landscape.
Furthermore, the company’s strategic focus on market dynamics and commercial readiness for a 2026 launch further supports the positive outlook. The discussions at the analyst event highlighted the potential for anito-cel to address unmet needs in the treatment of multiple myeloma, reinforcing the confidence in its market potential. These factors collectively underpin the Buy rating and the target price set by Gil Blum.